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explore impact of modality of boost radiotherapy (electron 
vs. HDR interstitial brachytherapy) on long term cosmesis. 
 
Material and Methods: 194 early breast cancer patients 
(T1N0, T2N0, T1N1) underwent BCS (Lumpectomy =125, 
Quadrentectomy = 69) + N3 nodal dissection in our unit 
between July 2004 and March 2010 after metastatic work up. 
Clips (4 or 5) were placed in all for subsequent delineation of 
radiotherapy target. Receptor status (including Her 2 neu) 
was detected for all. All patients received post BCS adjuvant 
chemotherapy - FEC for 'low risk' cases and EC X 4 then 
taxane X 4 for 'intermediate' and 'high risk' cases. Whole 
breast radiotherapy was given to all (50 Gy/ 25 fractions with 
CT-based planning). 145/194 patients also received boost - 
either 15 Gy/ 6 fractions electron or 10 Gy/ single fraction 
HDR interstitial implant (2 or 3-planes) with individualized 
CT-based planning and geometrical optimization. DVH was 
analyzed in each for D90, Coverege index, Dose received by 
skin, DNR and COIN. Cosmetic outcome was analyzed in each 
follow up visit using 4-point scale (excellent, good, fair, 
poor).  
 
Results: Out of evaluable 173/ 194 patients (4 died of 
metastasis, 17 lost to follow up) with minimum duration of 
follow up of 36 months, 86 did receive electron boost and 38 
received HDR. Local recurrence was in none so far. The PTV 
differed significantly - median 38 cc with HDR vs. median 90 
cc with electron. Cosmetic outcome was significantly 
different – only 48/86 patients receiving electron boost have 
'excellent and good' cosmesis compared to 31/38 receiving 
HDR brachytherapy (P = 0.008). Grade 1-2 fibrosis was seen in 
39/86 (46%) with electron and 6/38 with brachytherapy (P= 
0.002). Grade 1-2 telengiectasia was also significantly lower 
with HDR brachy 3/38 vs 29/86 with electron (P= 0.0019). 
Arm oedema was negligible in all patients - only 2.8%. 
 
Conclusion: For best cosmetic outcome after BCS, HDR 
brachytherapy (with CT-based 3D planning) for patients 
requiring boost radiotherapy appears to be much better 
option compared to electron unless the tumour is very 
superficial.  
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Purpose or Objective: Since2004 breast cancer patients have 
been prospectively included in three clinicaltrials using post-
operative permanent breast seed implant (PBSI) 
brachytherapy.We report the long term efficacy results of 
the technique on patients with lowrisk, small (less than 3 cm) 
and node negative tumors. 
 
Material and Methods: Thefirst trial was a Phase I/II accruing 
patient with low risk infiltrating ductalcarcinoma (IDC), the 
second trial was a Phase II trial DCIS patients, and the 
thirdtrial was a Multicentre Registry. All patients received 
PBSI delivering a doseof 90 Gy after CT-simulation and 
planning. Stranded 103Pd seeds wereimplanted using light 
sedation, ultra-sound guidance, fiducial needle 
localization,and using template. Patients werefollow-up 
annually for 10 years. Overall survival, disease free survival, 
localrecurrence and ipsilateral recurrence at 5 years were 
compared to theoreticalones calculated using theIDCTuft 
University IBTR and DCIS Memorial Sloan Kettering Cancer 
Center nomograms. 
 
Results: FromApril 2004 to May 2014, a total of 134 patients 
have been accrued. The median FUof the entire series is 58.6 
months [range 1.3 to 121.8 months]. The median ageat 
surgery was 61.9 years old [41 to 84.5], 91% of patients had 
an invasivetumor and the remaining were DCIS. All patients 
were T1-2 N0, grade 1 or 2 butone was found node positive 
on pathology review. At time of evaluation 119 patientswere 
without any evidence of disease. The local recurrence free 
survival at 5years was 98.8% (SD ± 1.20%), which was not 
statistically significantlydifferent to the theoretical rate of 
98.6% for patients receiving whole breastradiotherapy 
(p=0.23). But this rate was significantly better than the 95.4% 
theoreticalrisk of local recurrence with surgery alone 
(RR=0.27, p<0.001), The 5 yearsoverall survival was 97.4% (SD 
± 1.91%) and the disease free survival was 96.4%(SD ± 2.07%). 
In terms of tolerance, 22% of patients had telangiectasia 
almostexclusively grade I at 2 years. This rate decreases over 
time to 16% at 8years. Of note 40% of the patients developed 
a palpable and asymptomaticinduration in the surgical scar. 
 
Conclusion: Long-term results suggest that PBSI is a well-
toleratedtreatment, with an efficacy similar to whole breast 
radiotherapy for wellselected early stage breast patients. 
This treatment represents a goodtreatment option for 
patients having difficulties attending prolongedradiotherapy 
protocols. 
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Purpose or Objective: The new methodology for end-to-end 
remote dosimetric quality audit for IMRT and VMAT 
treatments for national dosimetry audit networks has been 
developed within a co-ordinated research project (CRP). The 
purpose of this audit is to verify the entire radiotherapy 
chain including imaging, treatment planning and dose 
delivery for a clinical IMRT treatment executed with either a 
static or rotating gantry. Overall 16 research groups from 13 
countries participate in this CRP. Results of a pilot study 
involving 6 CRP participants are presented. 
 
Material and Methods: A polystyrene phantom (see Fig. 1) 
was designed for this exercise with the solid water structures 
representing PTV and OAR. Each participant received a 
phantom preloaded with a custom cut EBT3 film and 4 TLDs 
(2 in PTV and 2 in OAR), extra TLDs for imaging and a set of 
instructions and datasheets. Participants were asked to scan 
the phantom, contour the structures, create the treatment 
plan and irradiate the phantom. The plan was generated as 
for a patient to deliver 4 Gy to PTV in 2 fractions and limit 
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the dose to OAR to 2.8 Gy (additional target objectives were 
provided).  
 
 
 
Fig. 1 IMRT phantom with an insert loaded with film and 
TLDs. 
Upon receipt of the irradiated phantom by the CRP organiser, 
TLDs and film were evaluated. Comparison was performed 
between the calculated and the film measured dose 
distributions using a gamma analysis tool (FilmQA ProTM, 
Ashland). The gamma acceptance criterion of 3%/3 mm over 
all pixel values exceeding 20% of the maximum dose was 
adopted. TLD results were presented as ratios of the TLD 
measured dose and the participant stated dose, 
D(TLD)/D(stat). 
 
Results: The results were obtained for 6 participants using 6 
different accelerator models, 4 MLC models, 3 TPS models 
and 5 dose calculation algorithms. All participants created 
treatment plans which fulfilled the dose constraints 
provided. The results of gamma evaluation were between 
93.5% and 100%. TLD results for PTV showed good agreement 
with the average D(TLD)/D(stat) = 0.995 and 1.2 % standard 
deviation (SD), whereas for OAR the average D(TLD)/D(stat) 
was 1.041 and the SD = 4.6%. As OAR was located in a high 
dose gradient region, even a 1 mm positional shift could 
cause significant TLD dose difference. 
 
Conclusion: The methodology of this audit, examined 
through a pilot study, proved to work well. The instructions 
and datasheets appeared to be clear and straightforward to 
follow. The results showed good agreement for TLDs in PTV 
and also between the planned and the film measured dose 
distributions. However, TLD measurements in the OAR were 
challenging because of the high dose gradient in this region. 
The results of the pilot study were used to assess the 
measurement uncertainties and will help in establishing the 
acceptance limits for audit results. The study continues with 
10 additional research groups involved in the CRP. 
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Purpose or Objective: Flattening filter free (FFF) beams 
have the potential to speed up breast cancer radiotherapy 
(RT) treatments and reduce whole body dose of a patient by 
reducing treatment head leakage. However, the near surface 
dose data of modulated FFF beams is lacking. In this work the 
surface doses were studied with various treatment plans for 
breast cancer RT with both FFF and flattening filter (FF) 
beams. 
 
Material and Methods: This study was executed with EBT3 
films irradiated in a cylindrical phantom (CIRS, ø16cm). The 
phantom was imaged with CT scanner (slice width 1 mm). 
PTV and critical organs were contoured to the 3D images 
(Fig.1). Four clinical treatment plans (photon energy 6 MV, 
fractional dose 2 Gy) were created for Elekta Infinity 
accelerator with Agility MLC: 1) tangential open field, 2) 
tangential IMRT with dynamic MLC (DMLC), 3) tangential 
VMAT (tVMAT) and 4) continuous VMAT (cVMAT) (Fig.1). Doses 
were calculated to water with X-ray Voxel Monte Carlo 
algorithm (XVMC, Monaco v5.00.04, Elekta) with a resolution 
of 1 mm and STD of 0.5%. Treatment plans were normalized 
to mean dose of PTV. All irradiations were repeated three 
times and the calibrated films were scanned in RGB mode. 
Red channel data was used in analysis with OmniProImRT 
software (v1.7, IBA, Germany). 
 
Results: Calculated and measured surface dose distributions 
were compared and are presented for FFF in Fig.1. The 
overall accuracy of XVMC calculation was good with the 
largest point dose difference of -11% recorded with FFF 
DMLC. Line dose analysis was performed in lateral and 
central parts of the phantom to evaluate surface doses with 
respect to beam directions (shown in Fig.1). Compared with 
measured dose the calculated doses were on average 3% 
larger at the depths of 0-2 mm (relevant depth for RT 
induced skin reactions). At 2-5 mm depths the dose deviation 
was on average 0% (Table 1). Central part surface doses at 0-
2 mm were on average 27% higher with open fields than with 
both VMAT techniques which was also well predicted by the 
TPS (max error 4%). Within the lateral parts the average 
surface doses between the techniques deviated less than 8% 
(range 45% - 48%). An important finding was also that on 
average the lowest values of surface doses were measured 
with open fields (lateral parts). No significant differences in 
surface doses were detected between FFF and FF techniques.
 
 
Fig.1: Calculated dose distributions of (A) open field, (B) 
tVMAT and (C) cVMAT treatment plans with FFF and the 
corresponding differences against the measured dose 
distributions (meas-calc) in D, E and F, respectively. 
Table 1:Measured and calculated surface doses of FFF and FF 
(depths of 0-2mm and 2-5mm). 
